Key Takeaways MOTS-c activates AMPK to increase fat oxidation and mitochondrial biogenesis, with a half-life of 46 hours requiring multiple weekly doses
Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
While anyone could benefit from a shot of B12, weve found that the best candidates are people who have a B12 deficiency, are struggling to get all the vitamins through a vegan or vegetarian diet, someone who is older, or someone who has digestive or autoimmune issues
Up to 60% of people have a version of this mutation leading to a decreased ability to absorb B12
Tiaminal B12 injection is also an option, with its own benefits